Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Amgen announces positive results from two Phase 3 BLINCYTO® (blinatumomab) studies In pediatric patients with relapsed acute lymphoblastic leukemia

worldpharmanewsSeptember 26, 2019

Tag: Amgen , BLINCYTO , lymphoblastic , leukemia , BiTE

PharmaSources Customer Service